{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-26-000146","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2026-07-15T11:49:04+00:00","discovered_at":"2026-07-15T11:50:00.223175+00:00","generated_at":"2026-07-15T11:50:12.856597+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"JNJ Q2 2026 revenue up 6.6% to $25.3B; adjusted EPS $2.90 (+4.7%)","bullets":["Q2 sales $25,310M (+6.6% operational, +1.0% currency); GAAP net earnings $5,534M (-0.1%).","GAAP diluted EPS $2.27 (-0.9%); adjusted diluted EPS $2.90 (+4.7%).","Innovative Medicine sales $16,384M (+7.8%); MedTech $8,926M (+4.5%).","US sales $14,533M (+7.3%); International $10,777M (+5.7%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-26-000146","json":"https://secwatch.observer/filing/0000200406-26-000146.json","markdown":"https://secwatch.observer/filing/0000200406-26-000146.md","text":"https://secwatch.observer/filing/0000200406-26-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/0000200406-26-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/jnj-20260715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T11:50:12.856597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}